Amphetamine/Dextroamphetamine Salts for Delayed Orgasm and Anorgasmia in Men

Laurence A. Levine MD
Hannah K. Betcher MD
Matthew J. Ziegelmann MD
Petar Bajic MD

1Rush University Medical Center, Chicago, IL; 2Mayo Clinic, Rochester, MN
Background & Methods

- Current treatments for delayed orgasm (DO) and anorgasmia (AO) are sub-optimal, with low rates of partial/complete response.
- We utilized amphetamine/dextroamphetamine salts (AMP; Adderall), a concentration-enhancing central nervous system stimulant, to treat DO/AO.
- We treated men with 5-20mg AMP 1-4 hours prior to sex from 2017-2019.
- Baseline characteristics were recorded and validated questionnaires were administered (IIEF, qADAM, Adult ADHD Self-Report Scale [ASRS]).
- Patients were contacted by phone and email to assess subjective orgasmic latency time (OLT), adverse effects and overall satisfaction.
- Predicters of treatment success were determined using multivariable logistic regression.
Results & Conclusions

- 17 men were treated with AMP – 6/17 (35.3%) w/ AO and 11/17 (64.7%) DO. Median f/u 1yr.
- 6/8 (75%) responders and 8/9 (88.9%) non-responders had failed other treatments.
- Among responders, AMP improved subjective experience of sex in 8/17 (47.1%), including 2/6 men with AO.
- 6/17 (35.3%; 1/6 with AO) had reduced OLT or increased frequency of orgasm.
- Among responders with DO and improved OLT, mean OLT during intercourse decreased by 72.3% (40.7 to 11.1 minutes, p=0.049).
- Minimal side effects were noted including insomnia and jitters in 1 patient each.

- AMP as a treatment for AO/DO merits further investigation.
- Measurable improvements in OLT or frequency of orgasm occurred in >1/3 of patients.
- Larger multi-center prospective trials are warranted.